Large-scale testing (Phase 3)Not Yet RecruitingNCT06855589
What this trial is testing
Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.
Who this might be right for
Prostate Cancer (Adenocarcinoma)
Charles LeMoyne Hospital 400